#ASH20 Allogene's David Chang makes the case for an off-the-shelf CAR-T in the jam packed anti-BCMA field
It’s hard to make a big mark in the anti-BCMA field.
The CAR-T JNJ-4528 from J&J and China’s Legend has been hogging the headlines recently with stellar results for advanced multiple myeloma, steadily advancing on the struggling ide-cel (bb2121) program from Bristol Myers Squibb and bluebird. And then there’s a passel of rivals hustling up everything from CAR-Ts to bispecifics and ADCs.
But Allogene $ALLO is trying hard to give them a run for the money.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.